Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium Patent Expiration
Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium is Used for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. It was first introduced by Entasis Therapeutics Inc
Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium Patents
Given below is the list of patents protecting Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xacduro (copackaged) | US10376499 | Combination therapy for treatment of resistant bacterial infections | Nov 17, 2035 | Entasis Therap |
| Xacduro (copackaged) | US9968593 | Combination therapy for treatment of resistant bacterial infections | Nov 17, 2035 | Entasis Therap |
| Xacduro (copackaged) | US9309245 | Beta-lactamase inhibitor compounds | Apr 02, 2033 | Entasis Therap |
| Xacduro (copackaged) | US9623014 | β-lactamase inhibitor compounds | Apr 02, 2033 | Entasis Therap |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium's patents.
Latest Legal Activities on Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium's Patents
Given below is the list recent legal activities going on the following patents of Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US9309245 |
| Notice of Final Determination- Ineligible | 26 Apr, 2024 | US10376499 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10376499 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US9309245 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US10376499 |
| Initial letter Re: PTE Application to regulating agency | 17 Jan, 2024 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US10376499 |
| Requirement for information sent under 37 CFR 1.750 | 17 Nov, 2023 | US9309245 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Oct, 2023 | US9309245 |
| Requirement for information sent under 37 CFR 1.750 | 09 Aug, 2023 | US10376499 |
Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium's Family Patents
